ClearView Healthcare Partners Interview: Cases, Format, and How to Prepare
ClearView Healthcare Partners evaluates candidates through life sciences case interviews and behavioral interviews. For its Connect to ClearView program, which mirrors the firm's standard interview process, selected applicants are notified within 1 week of the application close date and complete 2 virtual interviews with the Consultant Recruiting Team: 1 case interview and 1 behavioral interview. You can practice a case free, no sign-up, to build your structure and math out loud before your round.
Updated
What the ClearView interview process looks like
ClearView Healthcare Partners is a strategy consulting firm founded in 2007 that works with biotech, pharmaceutical, and medical devices and diagnostics clients across offices in Boston (headquartered in Newton, Massachusetts), New York, San Francisco, London, Zurich, and Gurgaon, India. Its standard interview process combines life sciences case interviews with behavioral interviews.
On its graduate opportunities page, ClearView documents how interviews run for Connect to ClearView, noting that those interviews match its standard interview process. Selected applicants hear back within 1 week of the application closing date to schedule 2 virtual interviews with members of the Consultant Recruiting Team. One session is a case interview and one is a behavioral interview.
If you are invited to in-person interviews, ClearView provides direct guidance on what to bring and how to handle the room. You can also work through our case interview examples and practicing case interviews with AI guides to get used to speaking your answers out loud.
- Dress in business formal attire for in-person interviews.
- Bring a pen and paper to take notes and work through your case interviews.
- Come ready to discuss your previous experience and how it relates to the specific role you are interviewing for.
- If you are interviewing for Connect to ClearView, be ready to explain your interest in the program and what you hope to gain from attending one of the 3-day immersion sessions.
What ClearView looks for during the case interview
ClearView cases test how you structure and solve commercial and clinical strategy problems in the life sciences. The firm outlines 5 specific habits to practice for the interview room, starting from the moment the interviewer reads the prompt.
When you build your structure, avoid generic templates. Review our guide on case interview frameworks to see how to build a split that fits the exact question asked.
- Listen closely to your interviewer and write down important information shared during the case.
- Create a framework built around the specific question you are trying to answer.
- Ask your interviewer clarifying questions throughout the case.
- Talk your interviewer through your thought process out loud as you work through the problem.
- Be willing to put a stake in the ground with a clear position, while staying flexible when your interviewer presents new information.
Official Practice Case 1: Inhaled insulin market sizing
ClearView publishes 2 official practice cases on its careers site and tells candidates to run through both to learn what to expect from life sciences cases. Practice Case 1 puts you in the role of advising a mid-sized pharmaceutical company developing an inhaled insulin product for the US diabetes market. The client wants to earn peak revenues of $300M per year in the US and asks whether that sales goal is realistic.
The case runs through 4 sequential questions (Questions A through D) that move from scoping the patient funnel to doing the market sizing math, evaluating clinical and commercial product factors, and making a final call. If you want extra speed on patient funnel arithmetic before trying this out loud, run through our case interview math drills and market sizing questions.
- Question A (Scoping the funnel): To determine the market size, ClearView states you must ask for 5 pieces of information: Prevalence of the Disease in the US, Disease Segmentation, Diagnosis Rate, Treatment Rate, and Pricing.
- Question B (Calculating market size and share): The research gives a 20M US diabetes prevalence, a 10% Type I and 90% Type II split, and 100% Type I and 65% Type II diagnosis rates. Insulin treatment rates are 100% for Type I and 1/3 for Type II, and the average price is $80 per month. From those inputs, you calculate the total market at $6B per year and the required market capture at 5%.
- Question C (Evaluating product adoption factors): To test whether 5% market penetration is realistic, ClearView highlights 6 key considerations: Efficacy, Safety, Convenience, Price, Onset of Action, and Biologic Variability. In the case findings, short- and long-term efficacy and short-term safety are strong, and the price matches existing therapies. However, long-term safety data is lacking compared to injectable insulin. Convenience is also limited because patients do not consider the inhaler travel size.
- Question D (Putting a stake in the ground): ClearView concludes that capturing 5% market share is unlikely. Because the inhaled product does not improve upon efficacy or safety over injectable insulin, the lack of a travel-size inhaler and the lack of long-term safety data are expected to severely limit uptake.
ClearView Practice Case 1: US Insulin Market Sizing Breakdown
| Funnel Step | Type I Diabetes | Type II Diabetes | Total US Market |
|---|---|---|---|
| US Disease Prevalence | 2M patients (10% of 20M) | 18M patients (90% of 20M) | 20M patients |
| Diagnosed Patients | 2M (100% of 2M) | 12M (65% of 18M, rounded in ClearView's key. Exact is 0.65 x 18M = 11.7M) | 14M diagnosed patients |
| Insulin-Treated Patients | 2M (100% of 2M) | 4M (1/3 of 12M) | 6M treated patients |
| Annual Price per Patient | ~$1,000/year ($80/mo x 12 = $960, rounded to ~$1,000) | ~$1,000/year ($80/mo x 12 = $960, rounded to ~$1,000) | ~$1,000/year per patient |
| Annual Market Size & Goal | $2B/year (by our calculation from ClearView's segment numbers) | $4B/year (by our calculation from ClearView's segment numbers) | $6B/year total ($300M goal = 5% capture) |
Official Practice Case 2: Acute myeloid leukemia (AML) strategy
ClearView's Practice Case 2 focuses on clinical mechanism of action, epidemiological incidence across age cohorts, and multi-asset portfolio strategy. Your client is a large, multinational biotechnology firm developing 3 very early-stage therapies for acute myeloid leukemia (AML), a rare, aggressive blood cancer with low survival rates and high relapse rates.
Two of the client's assets are oral small-molecule pills that each inhibit a distinct disease-related biomarker. The third asset is an IV infusion immuno-oncology (IO) agent that engages T cells against any cell expressing a specific antigen found broadly on leukemic cells, as well as on some healthy cells.
- Question A (Estimating annual US AML incidence): The client provides an incidence of ~1/100,000 for people under age 60 and ~10/100,000 for people over age 60. Assuming a 320M US population and an 80-year average lifespan with equal distribution across ages (~4M people per year of age), 240M people are younger than 60 (60 x 4M) and 80M people are older than 60 (20 x 4M). Applying 1/100,000 to 240M gives ~2,400 patients under 60, and applying 10/100,000 to 80M gives 8,000 patients over 60, for a total of ~10,400 incident AML patients annually in the US.
- Question B (Matching mechanism of action to treatment stage): ClearView divides AML treatment into 4 stages: induction (short bouts of high-intensity chemotherapy to de-bulk leukemic cells), consolidation (additional chemotherapy to push the patient into remission), maintenance (longer-term therapy to prevent re-emergence), and salvage (further intensive chemotherapy if a patient relapses or is refractory). Asked which stage to target with the IO drug, ClearView notes that any high-bulk disease stage (induction, consolidation, or salvage) works, and what matters is your scientific reasoning. High-bulk settings suit IO because the drug directly engages leukemic cells rather than relying solely on cytotoxic chemotherapy. By contrast, the target antigen also appears on healthy cells such as granulocytes and lymphocytes, which makes long-term maintenance risky.
- Question C (Weighing portfolio pros and cons): Asked for the pros and cons of developing 3 assets for a single indication, ClearView lists Pros as having more shots on goal if one asset fails, increasing revenue if multiple succeed and can be combined, reaching a wider swath of patients, and reducing competitor impact. Cons include higher clinical development costs and the risk of cannibalization in a small (~10,400 annual incident) patient population if the drugs are not sufficiently differentiated.
Behavioral interview prep and ClearView's 5 core values
For the behavioral interview, ClearView recommends stepping back and asking yourself two questions: what competencies are needed to be a great consultant, and what types of questions could an interviewer ask to test those competencies? ClearView also advises candidates who are new to behavioral interviewing to research the format so they can respond in a complete and succinct manner.
When you map out your stories, ground them in ClearView's 5 core values and project setup. ClearView uses a single staffing model where you work on 1 project at a time for 4 to 6 weeks on a team of 4 to 6 people. You can practice delivering concise stories using our consulting behavioral interview questions guide.
- Own It: Put your best foot forward. Prepare a story where you took full ownership of a workstream or research problem and drove it to a clear presentation.
- Solve It: Create impact through curiosity. Prepare an example where you combined scientific or analytical rigor with secondary and primary research to solve an ambiguous problem.
- Team First: Build the house we want to live in. Show how you collaborate in close-knit 4 to 6 person teams and support peers under tight timelines.
- Trusted Partner: Commit to quality and collaboration. Highlight a moment where you translated complex data or scientific findings into reliable, actionable guidance for a stakeholder or client.
- Ever Better: Embrace the challenge in every day. Share how you seek coaching, act on feedback, and pick up new skills across unfamiliar therapeutic areas.
7-step preparation plan from ClearView's recruiting guidance
ClearView lists 7 specific steps on its Explore Opportunities page to prepare for life sciences case interviews. We organized them into a checklist you can work through in the weeks leading up to your first round.
- Step 1: Read a case prep book to learn the standard flow and structure of a consulting case interview.
- Step 2: Study different types of cases so you know which commercial and clinical elements to consider when facing unique prompts.
- Step 3: Run through ClearView's Practice Case 1 (Inhaled Insulin) and Practice Case 2 (AML) on its website to see how epidemiology, mechanism of action, and commercial sizing fit together.
- Step 4: Join your university's consulting club and enter case competitions to practice problem-solving alongside your peers.
- Step 5: Attend case workshops to learn casing techniques and nuances from people with more case experience.
- Step 6: Practice casing one-on-one out loud with a friend or AI interviewer so your real interview is not the first time you speak a case out loud.
- Step 7: Read life sciences industry news sources regularly to stay current on biopharma, medtech, and pricing and market access trends (such as ClearView's published topics on AI in biopharma commercialization, PBM pricing and Express Scripts, obesity pharmacotherapy, vaccines, and bispecific T-cell engagers and CAR T).
Roles, degree requirements, and application timelines
ClearView recruits across 3 primary tracks: Undergraduate and Master's students, PhD/MD and Post-doc candidates, and Experienced hires (including MBAs and lateral consultants). While entry-level Consultants hold advanced degrees such as an MD or PhD, ClearView uses a merit-based promotion system that allows capable Senior Analysts to be promoted directly into the Consultant role and beyond without returning to school for an advanced degree.
ClearView Healthcare Partners Roles, Backgrounds, and Application Timelines
| Role / Program | Target Background & Experience | Official Application Timeline |
|---|---|---|
| Summer Analyst Internship (9-week program in SF, NYC, Boston, or London) | Undergraduate and 2-year master's students (rising seniors) | Opens in July for US applicants. Opens in September for UK applicants |
| Entry Level Analyst | Graduating with a bachelor's or master's degree in the life sciences and demonstrated interest in healthcare | Opens in July for US applicants (check university career site for school-specific deadlines) |
| Data Analyst | Bachelor's or master's degree in statistics, computer science, or a related field with healthcare interest | Currently not accepting applications per ClearView's undergraduate careers page |
| Connect to ClearView (3-day spring immersion in Newton, MA or London) | PhD, post-doc, or MD candidates in life sciences aiming to complete degree/post-doc in 2026, available in April and May 2025 | Two deadlines: Saturday, February 15, 2025, and Wednesday, March 5, 2025 (3 sessions in Newton, 1 in London) |
| Entry Level Consultant | Completing an advanced degree in the life sciences (e.g., MD, PhD) | Primarily hired through Connect to ClearView. Opens in September or October if additional hiring needs exist |
| Experienced Analyst & Senior Analyst | Bachelor's or master's in life sciences + at least 1 year of life sciences consulting experience (Analyst) or over one and a half years (Senior Analyst) | Posted on ClearView's careers page as openings arise |
| Experienced Consultant | Advanced degree in life sciences (MD, PhD) + at least 1 year of experience in life sciences consulting | Posted on ClearView's careers page as openings arise |
| Senior Consultant (MBA & Experienced) | At least 2 years of pre-MBA professional experience (MBA track), or advanced degree in life sciences/MBA + at least 2 years of life sciences consulting experience | Follows required timelines of respective MBA programs. Posted anytime needs arise for lateral hires |
| Engagement Manager, Associate Principal, Principal / Managing Director | Demonstrated leadership and consulting skills across multiple simultaneous projects and client relationships | Internal promotion and experienced hire postings as needed |
How to verify your ClearView interview invitation
ClearView posted an official fraud alert after learning of a spear-phishing scam targeting job applicants who posted resumes or applied on job sites. In the scam, individuals received fake interview invitations and job offer letters using ClearView's logo that requested money and personal information such as tax forms.
ClearView states that most of the fraudulent emails came from the address d.dias@clearviewhcp.quebec, which is not a valid company email. If you have any questions about whether an interview invitation or email from ClearView is authentic, verify it by emailing careers@clearviewhcp.com directly. Ready to rehearse your case and fit answers before your round? Practice with Soreno's AI interviewer or see a real sample report to check how your structure and math are scored.
From ClearView Healthcare Partners: Explore Opportunities, ClearView Healthcare Partners: Opportunities for PhD Students, MD Students, and Post-docs, ClearView Healthcare Partners: Opportunities for Undergraduate and Master's Students, ClearView Healthcare Partners: Opportunities for Experienced Hires, ClearView Healthcare Partners: Official Practice Case #1 (Inhaled Insulin), ClearView Healthcare Partners: Official Practice Case #2 (Acute Myeloid Leukemia), ClearView Healthcare Partners: Who We Are, Why ClearView, FAQ, and Careers, clearviewhcp.com and clearviewhcp.com.
1 practice question and sample answer
Say your answer out loud first, then read the sample answer.
Practice question
ClearView Practice Case 2 (Question B & C synthesis): Your biotech client is developing two oral biomarker inhibitors and one IV immuno-oncology (IO) T-cell engager for acute myeloid leukemia (AML), which has ~10,400 annual incident US patients. The IO drug targets an antigen expressed broadly on leukemic cells, but also on some healthy cells. Across the four AML treatment stages (induction, consolidation, maintenance, and salvage), where should the client position the IO asset, and how does it fit with the two oral inhibitors?
Sample answer. Example answer written by our team. The applicant is invented. I recommend positioning the IV immuno-oncology agent in a high-bulk disease setting, specifically starting in relapsed or refractory salvage therapy or frontline induction, while keeping it out of long-term maintenance. Here is the clinical and commercial reasoning. First, on mechanism of action: the IO agent engages T cells against a broad leukemic antigen. In high-bulk stages like induction, consolidation, or salvage, directly engaging T cells to clear leukemic blasts offers a clear clinical rationale over relying on standard cytotoxic chemotherapy alone. However, because that antigen is also expressed on healthy cells like granulocytes and lymphocytes, prolonged administration in a low-disease maintenance setting creates ongoing off-tumor toxicity risks that clinicians and patients will be reluctant to tolerate. Second, looking at the broader three-asset portfolio across an incident US population of about 10,400 patients a year: having three assets gives the client more shots on goal and potential combination revenue, but risks cannibalization if all three chase the exact same patients. Positioning the broad IV IO agent for acute de-bulking in induction or salvage, while reserving the oral small-molecule inhibitors for biomarker-selected maintenance or targeted combination regimens, differentiates the assets and covers more of the patient treatment sequence.
It puts a stake in the ground in the first sentence, connects the drug's mechanism of action and healthy-cell toxicity directly to the four clinical stages from ClearView's prompt, and ties the clinical recommendation back to the portfolio cannibalization tradeoff in a 10,400-patient market.
Practice the case interview, out loud
Soreno's AI interviewer runs a full case one question at a time, checks your math and scores your structure, any time you have 30 minutes.
Questions people ask
What is the format of the ClearView Healthcare Partners interview?
ClearView's standard interview process consists of case interviews and behavioral interviews. For the Connect to ClearView program, which follows the standard interview format, selected applicants are notified within 1 week of the deadline and complete 2 virtual interviews (1 case interview and 1 behavioral interview) with members of the Consultant Recruiting Team.
What types of case questions does ClearView Healthcare Partners ask?
Based on the 2 official practice cases on ClearView's website, candidates solve life sciences strategy problems involving US epidemiological market sizing (using prevalence, incidence by age, diagnosis rate, treatment rate, and pricing), testing whether a revenue target like $300M/year is realistic, matching a drug's mechanism of action to clinical treatment stages (such as induction, consolidation, maintenance, or salvage in AML), and weighing the pros and cons of developing multiple assets for one indication.
Do you need a PhD or MD to become a Consultant at ClearView?
Entry-level Consultants joining straight from graduate programs hold an advanced degree in the life sciences such as an MD or PhD. However, ClearView also promotes internally on merit, enabling capable Senior Analysts (who enter with a bachelor's or master's degree in the life sciences) to grow into the Consultant role and beyond without earning an advanced degree.
What is Connect to ClearView and when are the deadlines?
Connect to ClearView is a 3-day immersion program held in spring (April and May 2025, with 3 sessions at headquarters in Newton, Massachusetts, and 1 session in London) where ClearView Managers lead PhD, MD, and post-doc candidates (completing their training in 2026) through a mock pharmaceutical development strategy engagement. The two application deadlines are Saturday, February 15, 2025, and Wednesday, March 5, 2025, and ClearView recommends applying by the first deadline before spots fill.
How is staffing structured on ClearView consulting projects?
ClearView uses a single staffing model, meaning you are staffed on only 1 project at a time so you can focus all of your effort on one client. A typical project runs for 4 to 6 weeks with a team of 4 to 6 people, which may include colleagues from other ClearView offices.
More guides
- Environmental Consulting Interview Questions and Answers
- McKinsey Acceptance Rate: Official Hiring Process & Stages
- Risk Consulting Interview Questions and Answers (2026)
- Consulting Presentation Slides: Structure, Charts & Build
- FTI Consulting Salary: Filings, Benchmarks & Pay (2026)
- Management Consulting Slide Deck: Structure and Guide
- CaseBasix Alternatives for Case Interview Prep (2026)
- Consulting Firm Hierarchy: Ranks at McKinsey, BCG and Bain
- Consulting Strategy Group: Services, Pay, and Vetting
- Deloitte Discovery Intern: How to Apply and Interview
- KPMG Verbal Reasoning Test: Format, Example and Prep
- Marketing and Strategy Consulting Firms Guide (2026)